FORMYCON AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.1 EUR | +2.36% |
|
-13.50% | -30.67% |
| Mar. 18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
| Mar. 18 | Fresenius Settles With Johnson & Johnson to Market Stelara Alternative | DJ |
| Sales 2023 * | 77.85M 83.31M | Sales 2024 * | 63.35M 67.8M | Capitalization | 691M 739M |
|---|---|---|---|---|---|
| Net income 2023 * | 75M 80.26M | Net income 2024 * | -12M -12.84M | EV / Sales 2023 * | 8.78 x |
| Net cash position 2023 * | 6.75M 7.22M | Net cash position 2024 * | 63.35M 67.8M | EV / Sales 2024 * | 9.9 x |
| P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-109
x | Employees | 224 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 42.17% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +2.36% | ||
| 1 week | -13.50% | ||
| Current month | -15.64% | ||
| 1 month | -17.07% | ||
| 3 months | -19.55% | ||
| 6 months | -25.10% | ||
| Current year | -30.67% |
1 week
37.65
43.00
1 month
37.6547.50
Current year
37.6557.00
1 year
37.6581.10
3 years
37.6594.10
5 years
14.6594.10
10 years
6.2294.10
| Managers | Title | Age | Since |
|---|---|---|---|
Stefan Glombitza
CEO | Chief Executive Officer | - | 16-09-30 |
Enno Spillner
DFI | Director of Finance/CFO | 55 | 23-03-31 |
Andreas Seidl
CTO | Chief Tech/Sci/R&D Officer | - | 22-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Olaf Stiller
FOU | Founder | 47 | 06-12-31 |
Peter Wendeln
BRD | Director/Board Member | 59 | - |
Klaus Röhrig
BRD | Director/Board Member | 47 | 20-12-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.47% | 17 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 39.1 | +2.36% | 16,546 |
| 24-04-22 | 38.2 | -1.16% | 24,448 |
| 24-04-19 | 38.65 | -2.64% | 8,463 |
| 24-04-18 | 39.7 | -1.24% | 18,632 |
| 24-04-17 | 40.2 | -6.51% | 29,768 |
Delayed Quote Xetra, April 23, 2024 at 11:36 am EDT
More quotes
Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.
Calendar
2024-05-12
- German Spring Conference
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
39.1
EUR
Average target price
95.25
EUR
Spread / Average Target
+143.61%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -30.67% | 718M | |
| +3.13% | 42.11B | |
| +48.83% | 40.08B | |
| +8.49% | 40B | |
| -10.82% | 26.87B | |
| +8.26% | 24.58B | |
| -23.69% | 18.44B | |
| +1.58% | 11.94B | |
| +32.83% | 11.66B | |
| +6.63% | 11.01B |
- Stock Market
- Equities
- FYB Stock
